Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study.

ABSTRACT:

Objectives

HER2 alterations are identified in 2%-4% of lung adenocarcinoma, indicating poor clinical outcomes. Chemotherapy alone (C) or in combination with bevacizumab (BC), immune checkpoint inhibitors (IC), or both (IBC) are standard options in the first-line setting; however, optimal therapy and beneficiary populations remain unclear.

Methods

Patients with Stage IV HER2-altered lung adenocarcinoma from four cancer centers in China were retrospectively analyzed. The patients received C, BC, IC, or IBC as the first-line treatments. Clinical outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated. The tumor immune microenvironment (TIME) characteristics were analyzed to explore the beneficiary populations with different treatments.

R

SUBMITTER: Wang X 

PROVIDER: S-EPMC12441807 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature